Arno Therapeutics

Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.  The company’s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men.